EP2890437B1 - Aerosol inhalation device - Google Patents

Aerosol inhalation device Download PDF

Info

Publication number
EP2890437B1
EP2890437B1 EP13759992.4A EP13759992A EP2890437B1 EP 2890437 B1 EP2890437 B1 EP 2890437B1 EP 13759992 A EP13759992 A EP 13759992A EP 2890437 B1 EP2890437 B1 EP 2890437B1
Authority
EP
European Patent Office
Prior art keywords
actuator
orifice
tubular element
longitudinal axis
nozzle block
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
EP13759992.4A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2890437A1 (en
Inventor
Gaetano Brambilla
Robert Johnson
David Andrew Lewis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiesi Farmaceutici SpA
Original Assignee
Chiesi Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46796380&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP2890437(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farmaceutici SpA filed Critical Chiesi Farmaceutici SpA
Priority to EP13759992.4A priority Critical patent/EP2890437B1/en
Publication of EP2890437A1 publication Critical patent/EP2890437A1/en
Application granted granted Critical
Publication of EP2890437B1 publication Critical patent/EP2890437B1/en
Revoked legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/02—Sprayers or atomisers specially adapted for therapeutic purposes operated by air or other gas pressure applied to the liquid or other product to be sprayed or atomised
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0021—Mouthpieces therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0065—Inhalators with dosage or measuring devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/02—General characteristics of the apparatus characterised by a particular materials
    • A61M2205/0233—Conductive materials, e.g. antistatic coatings for spark prevention
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/02—General characteristics of the apparatus characterised by a particular materials
    • A61M2205/0238—General characteristics of the apparatus characterised by a particular materials the material being a coating or protective layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2209/00—Ancillary equipment
    • A61M2209/06—Packaging for specific medical equipment

Definitions

  • the present invention relates to the field of inhalers for medicaments and in particular to an improvement of aerosol devices for transferring to the respiratory system of a patient and in particular to the lungs, by oral inhalation, a metered dose of a medicament contained in a pressurised dispensing container.
  • pMDIs are aerosol delivery systems designed to deliver a medicament formulated with a pressure liquefied propellant gas and optionally at least one suitable additive. pMDIs are designed to meter a predetermined amount of the medicament, completely dissolved (in solution) or in form of micronized solid particles dispersed or suspended in the formulation and to dispense the dose as an inhalable aerosol cloud or plume.
  • a conventional pMDI is shown in Fig. 1 .
  • the pMDI comprises an actuator 1 comprising, in its vertical hollow portion, a housing adapted to receive a canister 2.
  • the canister 2 contains a formulation wherein the medicament is in solution or in suspension with a low boiling point propellant system optionally comprising at least one suitable pharmaceutically acceptable additive.
  • the canister 2 is normally provided with a metering valve having a hollow valve stem 3 for measuring discrete doses of the medicament formulation. The dose is dispensed as an inhalable cloud or plume 4.
  • Typical actuators 1 have a nozzle assembly or nozzle block 5 which receives the hollow valve stem 3 of the aerosol canister 2.
  • the nozzle block 5 defines the walls of the valve stem receptacle 13, expansion chamber or sump 6, and orifice 7 which ends in an aperture 8 having an enlarging frusto-conical section terminating in a cylindrical parallel sided portion.
  • the orifice 7 through its aperture 8 serves to propel the aerosol formulation into the mouthpiece portion, towards a mouthpiece opening 10 and assists in atomization of the aerosol formulation.
  • the orifice 7 has been provided such that its longitudinal axis is aligned with a longitudinal axis 9 of the actuator mouthpiece portion, so that the aerosol exits the orifice in a mean direction towards a mouthpiece opening 10.
  • the longitudinal axis of the orifice 7 in the nozzle block 5, aligned with the longitudinal axis 9 of the mouthpiece portion, is normally located at an angle greater or equal to 90°, preferably in the range from approximately 90° to approximately 120°, and more preferably from approximately 90° to approximately 110° to the direction of the longitudinal axis of the hollow valve stem 3 of the aerosol canister 2. Therefore when the canister 2 is actuated, the formulation containing the propellant moves down the stem 3 and expands within the expansion chamber 6 before being propelled through the orifice 7 from its aperture 8 towards the mouthpiece opening 10.
  • the formulation therefore, is atomised in a direction extending at an angle from approximately 90° to approximately 120° and preferably 110° with respect to the longitudinal axis of the aerosol canister 2.
  • the medicament is discharged in response to the user actuation performed by moving the canister relative to the valve stem, in the same time the medicament is inhaled by the user through the mouthpiece opening, creating an airflow entering from the spaces between the external walls of the canister and the internal walls of the vertical portion of the actuator, located upstream from the mouthpiece portion.
  • inhalers of this type are normally designed to be as small as practical for the convenience of users, the distance between the point at which the medicament is fired into the airflow and the patient's mouth is usually quite small so that there is little distance to reduce the inertia of the particles of medicament, with the result that coarse, non-respirable (>9 ⁇ m aerodynamic diameter) aerosol particles may impact and deposit in the mouth, throat and pharynx walls.
  • GB-A-2279879 and EP-A-0839544 disclose inhalers in which air inlets are arranged such that during inhalation an air flow is created which has a component directed away from the mouthpiece towards the aerosol spray.
  • the reverse airflow component is intended to create turbulence and slow the velocity of the medicament particles.
  • EP-A-862921 discloses similar devices comprising also a flow controller manually depressible to unseal the air inlets.
  • WO93/05837 and US-A-4972830 disclose inhalers in which the passage which directs the pressurised medicament from the canister to the chamber has particular configurations to reduce the velocity of the spray and enhance dispersion of the medicament in the airflow.
  • EP-A-0412648 discloses an inhaler in which a frusto-conical diverter with a small orifice is positioned in the path of the spray before the mouthpiece. Aerosol droplets are said to predominantly pass through the small orifice, decelerate and be inhaled while the propellant gas is predominantly diverted away from the mouthpiece out of the inhaler.
  • WO 00/50112 relates to actuators arranged as to inhibit airflow due to patient in the vicinity of the orifice of the nozzle block.
  • the actuator is designed such that atomized spray may be emitted from the orifice with a longitudinal axis which coincides with the longitudinal axis of the canister.
  • the correct use of this actuator depends on the inspiratory effort and timing of the patient, moreover the manufacture of such a device is more complex and expensive than a conventional pMDI.
  • EP-A2-0132352 , US 3,361,306 and US-A1-2012/0085345 describe devices for dispensing medicaments from pressurised containers having an outlet spout provided internally with an outlet member having a small (capillary passage) arranged at one end to receive contents discharged from the pressurised container and terminating at the other hand in an outlet directed towards the outlet end of the spout.
  • these devices are not intended for oral inhalation of drugs for the treatment of lung or pulmonary diseases but simply consist in spray applicator devices for local treatment of conditions of the nose, mouth or throat.
  • an actuator for an aerosol inhalation device as defined in the appended claim 1, including a tubular element positioned to enclose the orifice aperture within a recess.
  • the tubular element is configured such that one of its terminal openings may be close fit to the nozzle block external surface, around the orifice aperture, so as to be in a continuous flow path with the orifice.
  • tubular element is configured such that one of its terminal openings is in a tight fit with the nozzle block external surface, around the orifice aperture, so as to be in a continuous flow path with the orifice.
  • tubular element may be welded to the nozzle block external surface, around the orifice aperture.
  • the tubular element may be formed on the lateral part of a shaped hollow cylindrical object suitable to be tightly fitted to the outside of the nozzle block, covering its lateral surfaces so as the tubular element is in a continuous flow path with the orifice.
  • tubular element, the nozzle block, the housing for the aerosol canister and the mouthpiece portion form a single piece moulded actuator.
  • the tubular element has an internal diameter from 2 to 15 mm, preferably from 3 to 12 mm, even more preferably from 5 to 7 mm and the particularly preferred diameter is equal to about 6 mm.
  • the tubular element has a length, i.e. the distance between its apertures, from 2 to 20 mm, preferably from 3 to 15 mm, even more preferably from 8 to 12 mm and the particularly preferred lengths are equal to about 9, 10 and 11 mm.
  • the tubular element may also have a conventional thickness for this kind of devices known to the skilled in the art, however, suitable tubular element thickness may be from 0.1 to 3 mm or more, preferably from 0.2 to 2 mm, more preferably from 0.8 to 1.2 mm and most preferably of 1 mm.
  • the tubular element or the shaped hollow cylindrical object comprising in its lateral side a tubular element, suitable to be tightly fitted to the outside of the nozzle block, may be formed of the same material as the nozzle block or of a different material specifically suited to its purposes.
  • a shaped hollow cylindrical object suitable to be tightly fitted to the outside of the nozzle block of an actuator for pMDI inhalers, covering its lateral surfaces and comprising in its lateral side a tubular element so as that the tubular element is in a continuous flow path with the nozzle block orifice.
  • an inhaler comprising the actuator of any one aspect or embodiment described herein, and a canister having a metering valve and containing a pressurised medicament formulation.
  • the canister comprises a valve stem to be fitted into the valve stem receptacle formed in the nozzle block.
  • a metered-dose inhaler actuator comprising a housing having a mouthpiece portion and a canister receiving portion configured to receive a canister.
  • the actuator further comprises a nozzle block disposed within the housing and defining a valve stem receptacle configured to receive a valve stem of the canister, an orifice in fluid communication with the valve stem receptacle to propel the aerosol formulation towards the mouthpiece opening and a tubular element extending in the mouthpiece portion from the orifice aperture in a longitudinal axis aligned with a longitudinal axis of the actuator mouthpiece portion and coinciding with the orifice longitudinal axis.
  • kit of parts comprising an actuator of an aerosol inhalation device, the shaped hollow cylindrical object suitable to be tightly fitted to the outside of the nozzle block and an aerosol canister containing a pressurised medicament formulation.
  • a method in which an actuator of any one aspect or embodiment described herein is used for dispensing an aerosol formulation from a canister.
  • the method may be used to dispense the aerosol formulation without interaction with a human or animal body.
  • the method may, for example, be used to dispense an aerosol formulation when priming a metered dose inhaler.
  • Another not claimed aspect is the use of an actuator comprising a tube element according to any aspect or embodiment described herein for the reduction of the non-respirable dose and consequent potential oro-pharyngeal deposition of the dispensed aerosol formulation on actuation of the inhaler.
  • tubular element manipulates the airflow internal to the mouthpiece portion of the actuator, creating an area of low velocity immediately after the orifice aperture and altering the expansion dynamics of the flashing liquid emitted by the orifice which results in significant advantages over the prior art.
  • Non respirable fraction is often associated with systemic side effects and oral candidiasis and dysphonia (in case of inhaled corticosteroid treatment).
  • PSD particle size distribution
  • An actuator according to the invention may remove the requirement for add-on devices, spacers or holding chambers such as the VolumaticTM and AeroChamber PlusTM, which prevent a large proportion of the coarse particles from the dose reaching the patient, but produce dramatically changes in the PSD with respect to "actuator only" products. This reduces the need to carry such for add-on devices which are cumbersome and is an additional factor considering patient compliance.
  • the patient generated airflow is identical to that generated in a conventional MDI actuator without the tubular element according to the invention. Duration of plume formulation and manner of patient use are also unaffected.
  • the aerosol formulation may be an aerosol solution formulation or an aerosol suspension formulation.
  • the aerosol formulation may contain at least one active ingredient in a propellant or in a propellant/solvent system and, optionally, further excipients.
  • an optional low volatility component such as glycerol may be present.
  • any eventual deposits of the medicament in the tubular element or in the mouthpiece portion of the actuator may be removed through conventional washing techniques.
  • active drug active drug
  • active ingredient active ingredient
  • active compound active compound
  • active substance active substance
  • therapeutic agent therapeutic agent
  • nozzle block or "nozzle assembly” are used as synonymous to define an almost cylindrical element, which accommodates the valve stem of the aerosol canister and directs the emitted dose towards the mouthpiece. It rigidly extends in the actuator housing adapted to receive the canister from a central internal position of its base.
  • aligned when referring to two axes means "coinciding or parallel to each other".
  • longitudinal axis refers to a centre longitudinal axis of the respective concavity of component.
  • Respirable fraction also termed “fine particle fraction” refers to an index of the percentage of active particles which would reach the deep lungs in a patient.
  • the respirable fraction is calculated by the ratio between the "respirable dose” and the “delivered dose”. They are evaluated in vitro using a Multistage Cascade Impactor such as an Andersen Cascade Impactor (Apparatus 1, United States Pharmacopoeia - USP34-NF29) fitted with a USP throat, also defined as induction port, according to procedures reported in common Pharmacopoeias.
  • a Multistage Cascade Impactor such as an Andersen Cascade Impactor (Apparatus 1, United States Pharmacopoeia - USP34-NF29) fitted with a USP throat, also defined as induction port, according to procedures reported in common Pharmacopoeias.
  • the “delivered dose” is determined from the cumulative deposition in the apparatus, while the “respirable dose”, also defined as “fine particle dose”, is calculated from the deposition on Stages 3 (S3) to filter (AF) corresponding to particles ⁇ 4.7 microns.
  • non-respirable dose is the amount of larger aerosol particles which, upon inhalation, impact within the mouth and throat of the patient and may be swallowed, potentially causing side effects. It is determined by the amount of the emitted aerosol particles blocked at the level of the USP throat.
  • FIG. 2 is a schematic cross-sectional view, taken along the center symmetry plane, of an actuator (1) for a pMDI inhaler according to the invention comprising a housing adapted to receive an aerosol canister containing a pressurised medicament formulation, provided with a metering valve and a hollow valve stem, a mouthpiece portion terminating in a mouthpiece opening 10 through which the user inhales, a nozzle block 5 defining a valve stem receptacle 13, an expansion chamber or sump 6, and an orifice 7 to propel the aerosol formulation towards the mouthpiece opening 8 characterized by the presence of a tubular element 11 extending in the mouthpiece portion from the orifice aperture 8 in a longitudinal axis 9 aligned with a longitudinal axis of the actuator mouthpiece portion and coinciding with the orifice 7 longitudinal axis, wherein said tubular element is positioned to enclose the orifice aperture 8 within a recess.
  • the tubular element 11 is configured such that one of its terminal openings may be close fit or in a tight fit to the with the nozzle block 5 external surface, around the orifice aperture 8, so as to be in a continuous flow path with said orifice.
  • One of the terminal openings of the tubular element 11 may be secured to the nozzle block external surface, around the orifice aperture to be in a continuous flow path with said orifice, using a suitable joining procedure such as welding, soldering or other suitable techniques such as by a chemical bonding process among which adhesive bonding, Adhesive bonding may be performed by depositing a suitable liquid adhesive or glue around the juncture circumference of one terminal opening of the tubular element and around the orifice aperture, optionally followed by curing the adhesive, e.g. with UV light.
  • the tubular element 11 may be formed on the lateral part of a shaped hollow cylindrical object 12 suitable to be tightly fitted to the outside of the nozzle block 5, covering its lateral surfaces, so as the tubular element 11 is in a continuous flow path with the orifice 7 and its aperture 8.
  • the hollow cylindrical object 12 and the tubular element 11 may be moulded in one piece, as a single unit, or, in alternative, they may be joined together around the lateral opening of the cylindrical object 12, at the level of the orifice aperture 8, and one of the terminal opening of the tubular element 11, using a suitable joining procedure such as welding, soldering or other suitable techniques such as by a chemical bonding process as described above.
  • tubular element 11, the nozzle block 5, the housing for the aerosol canister and the mouthpiece portion of the actuator 1, according to the present invention may be moulded in one piece, as a single unit through single injection moulding tools.
  • the injection moulding using the suitable tool permits to manufacture in a single piece an actuator plus nozzle tube element with a smoothed gradient between the frusto-conical section of the orifice aperture 8 and the tube opening, as shown in Figures 16A-16B , or with a stepped feature between the orifice aperture 8 and the tube opening, as shown in Figures 17A to 17C .
  • Actuation of the metering valve of the aerosol canister allows one dose of the formulation to be released from the valve through the stem 3, and propelled towards the mouthpiece opening passing respectively through the intermediate sump 6, orifice 7 and tubular element 11.
  • the tubular element 11 has a substantially cylindrical shape, opened at the two bases and with an internal diameter from 2 to 15 mm, preferably from 3 to 12 mm, even more preferably from 5 to 7 mm and a particularly preferred diameter is equal to about 6 mm.
  • the tubular element 11 has a length, i.e. the distance between its apertures, from 2 to 20 mm, preferably from 3 to 15 mm, even more preferably from 8 to 12 mm and particularly preferred lengths are equal to about 9, 10 and 11 mm.
  • Tubular elements with manufacturing tolerances of ⁇ 0.2 mm and preferably of ⁇ 0.1 mm with respect to a given diameter and/or length are acceptable and may be considered included in the present invention.
  • the tubular element 11 may also have a conventional thickness for this kind of devices known to the skilled in the art; however, suitable tubular element thickness may be from 0.1 to 3 mm or more, preferably from 0.2 to 2 mm, more preferably from 0.8 to 1.2 mm and most preferably 1 mm. In this case, manufacturing tolerances of from ⁇ 0.05 to ⁇ 0.2 are acceptable and are also included in the present invention.
  • FIG. 20 Alternative embodiments of the invention represented in Figure 20 comprise tubular elements with a substantially cylindrical shape wherein non-parallel tubes as well as parallel tubes with an outer lip are provided and which may be categorised by the following geometric profiles:
  • the actuator 1, the nozzle block 5, the tubular element 11 and /or the shaped cylindrical object 12 may be formed of different materials and with different specifications which are suited for their specific purposes.
  • suitable materials include metal materials such as aluminium, aluminium alloy or stainless steel; but also plastic polymeric materials, such as thermoplastic resins, optionally UV curable, including different grades polypropylene (PP) the material of first choice in general for the pMDI actuators, polyethylene (i.e. HDPE, high density PE); fluorinated polymers such as polytetrafluoroethylene (PTFE); acrylonitrile-butadiene-styrene (ABS); polyacrylate such as polymethyl methacrylate (PMMA); polycarbonate (PC); polyamide (i.e. nylon); polyester such as polyethylene terephthalate (PET).
  • the plastic polymeric materials may be coated with antistatic agents by means of a moulding or a coating process.
  • the lateral surface of the tubular element 11 may be continuous or in alternative, perforated by one or more holes of optimised shapes (for instance round, square or rhomboid) and dimensions, disposed linearly or opposed each other and at different lengths and positions with respect to its opening in the mouthpiece portion of the actuator.
  • optimised shapes for instance round, square or rhomboid
  • the lateral inner surface of the tubular element 11 may also present different alternative surface textures, in fact it may be smooth or wrinkled, with different degrees of roughness, to optimise the performance of the device.
  • the tubular element 11, the shaped hollow cylindrical object 12 suitable to be tightly fitted to the outside of the nozzle block and comprising in its lateral side a tubular element 11, or a single piece moulded actuator comprising the tubular element 11, the nozzle block 5, the housing for the aerosol canister 2 and the mouthpiece portion 9 are suitable for use in dispensing of a drug formulation to a patient through conventional pMDI inhalation devices.
  • the pMDI inhalation devices are known in the art. Said devices comprise a canister fitted with a metering valve.
  • Part or the entire canister may be made of a metal, for example aluminium, aluminium alloy, stainless steel or anodized aluminium.
  • the canister may be a plastic can or a plastic-coated glass bottle.
  • the metal canisters may have part or all of their internal surfaces lined with an inert organic coating.
  • preferred coatings are epoxy-phenol resins, perfluorinated polymers such as perfluoroalkoxyalkane, perfluoroalkoxyalkylene, perfluoroalkylenes such as poly-tetrafluoroethylene (Teflon), fluorinated-ethylene-propylene (FEP), polyether sulfone (PES) or fluorinated-ethylene-propylene polyether sulfone (FEP-PES) mixtures or combination thereof.
  • Other suitable coatings could be polyamide, polyimide, polyamideimide, polyphenylene sulfide or their combinations.
  • canisters having their internal surface lined with FEP-PES or Teflon may be used.
  • canisters made of stainless steel may be used.
  • the canister is closed with a metering valve for delivering a daily therapeutically effective dose of the active ingredient.
  • the metering valve assembly comprises a ferrule having an aperture formed therein, a body moulding attached to the ferrule which houses the metering chamber, a stem consisting of a core and a core extension, an inner- and an outer- seal around the metering chamber, a spring around the core, and a gasket to prevent leakage of propellant through the valve.
  • the gasket seal and the seals around the metering valve may comprise elastomeric material such as EPDM, chlorobutyl rubber, bromobutyl rubber, butyl rubber, or neoprene. EPDM rubbers are particularly preferred.
  • the metering chamber, core and core extension are manufactured using suitable materials such as stainless steel, polyesters (e.g. polybutyleneterephthalate (PBT)), or acetals.
  • the spring is manufactured in stainless steel eventually including titanium or other inert metal alloys.
  • the ferrule may be made of a metal, for example aluminium, aluminium alloy, stainless steel or anodized aluminium. Suitable valves are available from manufacturers such as Valois, Bespak plc and 3M-Neotechnic Ltd.
  • the pMDI is actuated by a metering valve capable of delivering a volume of between 25-100 ⁇ l, preferably between 40-70 ⁇ l, and optionally about 50 ⁇ l, or about 63 ⁇ l per actuation.
  • valve stem is seated in a nozzle block which has an orifice leading to an expansion chamber.
  • the expansion chamber has an exit orifice 7 which extends into the mouthpiece.
  • Actuator (exit) orifices having a diameter in the range 0.15 - 0.45 mm and a length from 0.30 to 1.7 mm are generally suitable.
  • an orifice having a diameter from 0.2 to 0.44 mm is used, e.g. 0.22, 0.25, 0.30, 0.33 or 0.42 mm.
  • actuator orifices having a diameter ranging from 0.10 to 0.22 mm, in particular from 0.12 to 0.18 mm, such as those described in WO 03/053501 .
  • the use of said fine orifices may also increase the duration of the cloud generation and hence, may facilitate the coordination of the cloud generation with the slow inspiration of the patient.
  • the canister contains an aerosol formulation which may be an aerosol solution formulation or an aerosol suspension formulation.
  • the aerosol formulation may contain at least one active ingredient in a propellant or in a propellant/solvent system and, optionally, further pharmaceutical acceptable additive or excipient.
  • the at least one active ingredient of the formulation may be any pharmaceutical active ingredient known in the art, administrable by inhalation alone or in combination for separate, sequential or simultaneous use.
  • the active ingredient is known for prophylaxis or treatment of respiratory diseases and their symptoms, and in particular in diseases characterized by obstruction of the peripheral airways as a result of inflammation and presence of mucus, such as asthma of all types, chronic obstructive pulmonary disease (COPD), bronchiolitis, chronic bronchitis, emphysema, acute lung injury (ALI), cystic fibrosis, rhinitis, and adult or acute respiratory distress syndrome (ARDS).
  • COPD chronic obstructive pulmonary disease
  • COPD chronic obstructive pulmonary disease
  • bronchiolitis chronic bronchitis
  • ALI acute lung injury
  • cystic fibrosis rhinitis
  • ARDS adult or acute respiratory distress syndrome
  • the at least one active ingredient is selected from the class of the beta-2 agonists, inhaled corticosteroids, anti-muscarinic agents, phosphodiesterase IV inhibitors and combinations thereof.
  • beta-2 agonist is selected from the group of salbutamol, (R)-salbutamol (levalbuterol) fenoterol, formoterol, arformoterol, carmoterol (TA-2005), indacaterol, milveterol, vilanterol (GSK 642444), terbultaline, salmeterol, bitolterol, and metaproterenol in form of single stereoisomers, diastereoisomeric mixtures, and a pharmaceutically acceptable salt thereof or hydrate thereof.
  • the inhaled corticosteroid is selected from the group of beclometasone dipropionate, fluticasone propionate, fluticasone furoate, butixocort, mometasone furoate, triamcinolone acetonide, budesonide and its 22R-epimer, ciclesonide, flunisolide, loteprednol, and rofleponide.
  • the anti-muscarinic agent is selected from the group of methscopolamine, ipratropium, oxitropium, tiotropium, glycopyrronium, aclidinium, umeclidinium, trospium and a salt thereof with a pharmaceutical acceptable counter ion.
  • More preferably phosphodiesterase IV inhibitor is selected from the group of cilomilast, piclomilast, roflumilast, tetomilast, CHF 6001 and a pharmaceutically acceptable salt thereof.
  • active ingredient may be selected from the group of beclometasone dipropionate, fluticasone propionate, fluticasone furoate, mometasone furoate and budesonide alone or in combination with one or more active ingredient selected from salbutamol, formoterol, salmeterol, indacaterol, vilanterol, glycopyrronium, tiotropium, aclidinium, umeclidinium and a salt thereof.
  • the most preferred active ingredients are selected from beclometasone dipropionate, budesonide, formoterol fumarate, beclometasone dipropionate - salbutamol sulphate combination, beclometasone dipropionate - formoterol fumarate combination and beclometasone dipropionate - formoterol fumarate - glycopyrronium bromide combination.
  • the propellant may be any pressure-liquefied propellant and is preferably a hydrofluoroalkane (HFA) or a mixture of different HFAs, more preferably selected from the group consisting of HFA 134a (1,1,1,2-tetrafluoroethane), HFA 227 (1,1,1,2,3,3,3-heptafluoropropane), and mixtures thereof.
  • HFA hydrofluoroalkane
  • HFA 227 1,1,1,2,3,3,3-heptafluoropropane
  • the solvent which may be incorporated into the formulation has generally a higher polarity than that of the propellant and may include one or more substances such as a pharmaceutically acceptable alcohol, in particular ethanol, a polyol, such as propylene glycol or polyethylene glycol, or mixtures thereof.
  • a pharmaceutically acceptable alcohol in particular ethanol
  • a polyol such as propylene glycol or polyethylene glycol, or mixtures thereof.
  • the solvent is selected from the group of lower branched or linear alkyl (C 1 -C 4 ) alcohols such as ethanol and isopropyl alcohol.
  • the co-solvent is ethanol.
  • the at least one pharmaceutically active ingredient of the formulation is substantially completely and homogeneously dissolved in the propellant/solvent, system, i.e. the composition is preferably a solution formulation.
  • the formulation may comprise other pharmaceutical acceptable additives or excipients known in the art which are substantially inert materials which are non toxic and do not interact in negative manner with other components of the formulation.
  • the formulation may comprise one or more co-solvent, surfactant, carbohydrate, phospholipid, polymer, wetting agent, stabiliser, lubricant or low volatility component.
  • an acid which may be organic or inorganic acid (mineral acids) which may be selected from pharmaceutically acceptable monoprotic or polyprotic acid, such as (but not limited to): hydrogen halides (hydrochloric acid, hydrobromic acid, hydroiodic acid etc.) phosphoric acid, nitric acid, sulphuric acid, halogen oxoacids.
  • Low volatility components are useful in order to increase the mass median aerodynamic diameter (MMAD) of the aerosol particles upon actuation of the inhaler and/or to improve the solubility of the active ingredient in the propellant/solvent system.
  • MMAD mass median aerodynamic diameter
  • the low volatility component when present, has a vapour pressure at 25°C lower than 0.1 kPa, preferably lower than 0.05 kPa.
  • low-volatility components are esters such as isopropyl myristate, ascorbyl myristate, tocopherol esters; glycols such as propylene glycol, polyethylene glycol, glycerol; and surface active agents such as saturated organic carboxylic acids (e.g. lauric, myristic, stearic acid) or unsaturated carboxylic acids (e.g. oleic or ascorbic acid).
  • the amount of low volatility component may vary from 0.1 to 10% w/w, preferably from 0.5 to 5% (w/w), more preferably between 1 and 2% (w/w).
  • an amount of water comprised between 0.005 and 0.3% (w/w) may optionally be added to the formulations in order to favourably affect the solubility of the active ingredient without increasing the MMAD of the aerosol droplets upon actuation.
  • FIGS. 3b and 4 show the basic premise of the design and the respective diameter D and length L of the geometries tested.
  • the smallest internal diameter of 3mm is less than the diameter of the orifice cone therefore was chamfered to prevent an impact surface and potential dead space from being created.
  • the largest tube diameters required a step detail to enable the extra width to be catered for, as the internal diameter was wider than the nozzle block of the actuator ( Figure 5 ).
  • tubular elements were manufactured in UV Curable Acrylic Plastic. All prototype tubes were fitted on actuators with 0.30 mm orifice diameter.
  • Drug delivery characterisation of the prototypes, in conjunction with the BDP 250 formulation, was determined with an Andersen Cascade Impactor (Apparatus 1, United States Pharmacopoeia - USP34-NF29) fitted with a USP throat, also defined as induction port, according to procedures reported in common Pharmacopoeias, at a flow rate of 28.3 ( ⁇ 5%) L min-1.
  • Andersen Cascade Impactor Apparatus 1, United States Pharmacopoeia - USP34-NF29
  • USP throat also defined as induction port
  • Drug deposition in each stage and in the induction port was quantified by UPLC/MS (Ultra-Performance Liquid Chromatography/Mass Spectrometry).
  • Aerosol characteristics determined include mass median aerodynamic diameter (MMAD), i.e., the diameter around which the mass aerodynamic diameters of the emitted particles are distributed equally; the delivered dose (DD) determined from the cumulative deposition in the apparatus, the fine particle dose (FPD) or respirable dose corresponding to the amount of particles of diameter ⁇ 4.7 ⁇ m; the fine particle fraction (FPF) which is the percent ratio between the FPD and the DD.
  • MMAD mass median aerodynamic diameter
  • DD delivered dose
  • FPD fine particle dose
  • FPF fine particle fraction
  • Figures 6 and 7 present data from both phases 1 and 2, demonstrating correlations between the length / diameter ratio (L/D) of the tubular element, the induction port deposition and FPD respectively.
  • Figure 7 shows that as the ratio is increased to greater than 2, the FPD begins to drop significantly, shifting the particle size distribution of the emitted aerosol particles away from that of the BDP 250 formulation emitted from a conventional actuator. This may be because the cone angle of the plume is restricted to such a degree that an increased number of the finer particles are impacted and retained on the tubular element in addition to the coarse fraction.
  • Table 4 below presents combined data sets of phases 1 and 2, which best match the particle size distribution of the tested formulation (BDP 250: Table 1). All of these tube geometries reduce induction port deposition by a similar mass with respect to the same formulation delivered through a conventional actuator while maintaining constant the performance in term of Fine particle dose, MMAD and GSD (Geometric Standard Deviation).
  • a range of single moulded actuators plus tubular elements of 10mm length and 6 mm diameter with smoothed or stepped nozzle tube features as shown in Fig. 16A-B and in Fig. 17A-C were manufactured and tested in their performances.
  • the plume temperature profile was also measured, to determine whether the presence of the nozzle tube could potentially reduce the "cold-freon" effect.
  • Prototype 204 was coupled with a new, unprimed can containing the solution formulation of beclometasone dipropionate 250 ⁇ g /dose (BDP 250 of Table 1).
  • BDP 250 of Table 1
  • Four doses were delivered to a waste Dose Unit Sampling Apparatus (DUSA; Copley Instruments, UK) every five minutes and all shot weights recorded. The five minute period allowed the ethanol to evaporate and the area around the orifice and nozzle tube to dry; this could be expected to occur between doses in everyday patient use.
  • a microscope photograph was taken of the orifice aperture and tubular element. Andersen Cascade Impactor (ACI) testing was carried out at beginning, middle and end of can-use-life. Following the exhaustion of the can, the device was washed to determine the ease with which the layer of deposit within the recessed nozzle could be removed.
  • ACI Andersen Cascade Impactor
  • Figure 8 presents the shot weight data for the through-can-life investigation.
  • the mean shot weight was 52.6 ⁇ 1.3 mg, calculated from all shot weights (199) excluding the priming shot 1. All shot weights (excluding priming) are well within ⁇ 15% of the mean recorded shot weight.
  • Plumes of the emitted aerosols were collected into a DUSA and temperature profiles were recorded by thermocouples (Omega, UK, K-Type, response time 3 ms) mounted 20 mm from the inlet of the DUSA. Data was collected continually by a PC using Dasylab Data Acquisition Software, to ensure that the entire plume temperature profile was captured, according to Brambilla, G. et al. Plume Temperature Emitted from Metered Dose Inhalers. Int. J. Pharm. 405(1-2), 9-15, 2011 .
  • MMPT Mean minimum plume temperature
  • the presence of the recessed tube element causes an overall increase in the plume temperature profile, compared with a conventional actuator (0.30 mm orifice diameter) as shown in Figure 10 .
  • the mean minimum plume temperature, MMPT, for the prototype is 0.9 ⁇ 0.4°C, compared with -5.9 ⁇ 1.9°C without the nozzle tube.
  • a warmer plume may cause less discomfort to the patient, which could have a more positive effect on patient compliance.
  • a tube element according to the invention demonstrated also a robust performance through-can-life, with consistent shot weight data and particle size distribution at beginning, middle and end of life of the canister.
  • the plume temperature profile is also favourable when compared to a conventional pressurised metered dose inhaler actuator without tube element.
  • Drug delivery data was collected for the marketed Clenil Modulite range, purchased in a pharmacy, which includes the dose strengths: BDP 250, 200, 100 and 50 ⁇ g/50 ⁇ l.
  • Fostair another marketed product, purchased in a pharmacy, based on a combination of the active ingredients beclometasone dipropionate and formoterol fumarate dihydrate 100 ⁇ g - 6 ⁇ g, respectively per 50 ⁇ l actuation of a pressurised inhalation solution including ethanol, hydrochloric acid and norflurane (HFA 134a.
  • the Fostair formulation does not contain glycerol.
  • Figure 15 and Table 8 demonstrate that an actuator with the tube element prototype 204 also functions effectively with the Fostair marketed formulation.
  • the delivered dose is reduced from 89 to 49 ⁇ g and 5.4 to 2.9 ⁇ g for BDP and formoterol respectively, as induction port deposition is decreased.
  • Fostair BDP data
  • Fostair Formoterol data Actuator Conventional Act. with Tube Elem Prototype 204 Conventional Act.
  • tube elements of dimensions corresponding to prototype 204 were manufactured in the following materials: aluminium, polytetrafluoro ethylene (PTFE), polypropylene (PP), stainless steel, nylon.
  • Drug delivery investigations on the actuator according to the present invention characterised by the presence of a tubular element, were also performed with a pressurised metered dose inhaler containing a combination of two active ingredients wherein a first active ingredient is dissolved in the formulation and micronized particles of a second active ingredient are dispersed in the formulation.
  • the actuator according to the invention results in an almost 50% reduction in the non-respirable dose both for beclometasone dipropionate and salbutamol.
  • Pertinent choice of the orifice sizes allows aerosol plume to match more closely the fine particle dose of the conventional, marketed product.
  • Tube Elem Prototype 270 Conventional Act. with Tube Elem Prototype 270 Delivered Dose ( ⁇ g) 216.9 158.5 128.6 82.4 FPD ( ⁇ g) 60.2 74.6 26.7 30.5 Non-Respirable Mass ( ⁇ g) 156.7 83.9 101.9 51.9 N 2 2 2 2 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Anesthesiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nozzles (AREA)
EP13759992.4A 2012-08-29 2013-08-23 Aerosol inhalation device Revoked EP2890437B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP13759992.4A EP2890437B1 (en) 2012-08-29 2013-08-23 Aerosol inhalation device

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12182122 2012-08-29
PCT/EP2013/067514 WO2014033057A1 (en) 2012-08-29 2013-08-23 Aerosol inhalation device
EP13759992.4A EP2890437B1 (en) 2012-08-29 2013-08-23 Aerosol inhalation device

Publications (2)

Publication Number Publication Date
EP2890437A1 EP2890437A1 (en) 2015-07-08
EP2890437B1 true EP2890437B1 (en) 2019-12-18

Family

ID=46796380

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13759992.4A Revoked EP2890437B1 (en) 2012-08-29 2013-08-23 Aerosol inhalation device

Country Status (22)

Country Link
US (2) US20140060531A1 (ru)
EP (1) EP2890437B1 (ru)
JP (1) JP2015531247A (ru)
KR (1) KR20150048727A (ru)
CN (1) CN104582771B (ru)
AR (1) AR092274A1 (ru)
AU (1) AU2013307389A1 (ru)
BR (1) BR112015002757A2 (ru)
CA (1) CA2883749A1 (ru)
CL (1) CL2015000475A1 (ru)
EA (1) EA033581B1 (ru)
HK (1) HK1209669A1 (ru)
IL (1) IL237428A0 (ru)
IN (1) IN2015DN01597A (ru)
MA (1) MA37871A1 (ru)
MX (1) MX2015002027A (ru)
PE (1) PE20150523A1 (ru)
PH (1) PH12015500208A1 (ru)
SG (1) SG11201501434PA (ru)
TN (1) TN2015000073A1 (ru)
TW (1) TW201420140A (ru)
WO (1) WO2014033057A1 (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023079173A1 (en) 2021-11-08 2023-05-11 Chiesi Farmaceutici S.P.A. Apparatus for administering medicaments and method for managing expiry dates of a medicament dispenser

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2513553B (en) * 2013-03-26 2015-03-18 Kind Consumer Ltd An Inhaler
PL3089735T3 (pl) 2013-12-30 2018-12-31 Chiesi Farmaceutici S.P.A. Trwała ciśnieniowa kompozycja roztworu aerozolowego kombinacji bromku glikopironium i formoterolu
GB201408229D0 (en) * 2014-05-09 2014-06-25 Norton Waterford Ltd Aerosol device
GB201408561D0 (en) * 2014-05-14 2014-06-25 The Technology Partnership Plc Aerosolisation engine for liquid drug delivery
TWI579008B (zh) * 2015-03-06 2017-04-21 崑山科技大學 Drug mist inhalation auxiliaries
JP6818008B2 (ja) 2015-07-20 2021-01-20 パール セラピューティクス，インコーポレイテッド エアロゾル送達システムおよび関連する方法
WO2017197277A1 (en) 2016-05-13 2017-11-16 MSI Coatings Inc. System and method for using a voc free low radiant flux led uv curable composition
US10098837B2 (en) * 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD
CA3032761C (en) * 2016-08-04 2022-06-07 Japan Tobacco Inc. Flavor inhaler with oscillator
CN109803702B (zh) * 2016-09-06 2022-04-12 医疗发展国际有限公司 用于可吸入液体的吸入器装置
BR112019012727B1 (pt) * 2016-12-20 2022-11-16 Emphasys Importadora Exportadora E Distribuidora Ltda Inalador de pó seco
US11338320B1 (en) * 2018-02-03 2022-05-24 MSI Coatings Inc. Composition for aerosol cans, method of making and using the same
CN110115790B (zh) * 2018-02-07 2021-08-06 心诚镁行动医电股份有限公司 雾化器组件及其气流主要导引件
US11304897B2 (en) 2020-06-09 2022-04-19 Anovent Pharmaceutical (U.S.), Llc Pharmaceutical formulation containing umeclidinium bromide and vilanterol trifenatate

Citations (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3361306A (en) 1966-03-31 1968-01-02 Merck & Co Inc Aerosol unit dispensing uniform amounts of a medically active ingredient
GB1219090A (en) 1967-05-22 1971-01-13 Moore Medicinal Products Ltd Pressurised aerosol dispensers for medicaments
EP0132352A2 (en) 1983-07-15 1985-01-30 Glaxo Group Limited Aerosol applicator device
US5069204A (en) 1989-08-23 1991-12-03 Riker Laboratories, Inc. Inhaler
WO1994027663A1 (en) 1993-05-26 1994-12-08 Minnesota Mining And Manufacturing Company Aerosol actuator
US5435297A (en) 1991-08-29 1995-07-25 Christoph Klein Medical device for inhaling metered aerosols
GB2312379A (en) 1996-04-25 1997-10-29 Bespak Plc Metered dose inhaler
US5682875A (en) * 1988-10-22 1997-11-04 Fisons Plc Aerosol device having a spout to prevent spray head blockage
US20030015191A1 (en) 2001-04-26 2003-01-23 New England Pharmaceuticals, Inc. Metered dose delivery device for liquid and powder agents
EP1321159A1 (en) 2001-12-21 2003-06-25 CHIESI FARMACEUTICI S.p.A. Pressurized metered dose inhaler (pMDI) actuators with laser drilled orifices
WO2004091704A1 (en) 2003-04-16 2004-10-28 Trudell Medical International Antistatic medication delivery apparatus
US20050274378A1 (en) * 2002-07-25 2005-12-15 Bonney Stanley G Medicament dispenser
GB2415388A (en) * 2004-06-24 2005-12-28 Link Holdings Ltd Medicament dispenser with an insert in the medicament flow path
US20060118107A1 (en) 2002-10-30 2006-06-08 King Michael L Tubular nozzles for use in systems for delivering medicaments
US20070175469A1 (en) 2005-12-02 2007-08-02 Boehringer Ingelheim International Gmbh, Dispensing device
US20070251950A1 (en) * 2003-12-12 2007-11-01 Clinical Designs Limited Dispenser and Counter
WO2008017575A1 (en) 2006-08-07 2008-02-14 Bang & Olufsen Medicom A/S An inhaler and a method of dispensing medication to a person
US20100218760A1 (en) 2006-08-22 2010-09-02 Anderson Gregor John Mclennan Actuator for an inhaler
US20110061646A1 (en) 2007-08-21 2011-03-17 Glaxo Group Limited Drug dispenser
US20110155129A1 (en) * 2009-12-23 2011-06-30 Map Pharmaceuticals, Inc. Enhanced eductor design
WO2011095762A1 (en) 2010-02-03 2011-08-11 Bacon Raymond J Dispenser
US20120085345A1 (en) 2010-10-12 2012-04-12 Teva Branded Pharmaceutical Products R&D, Inc. Nasal spray device

Patent Citations (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3361306A (en) 1966-03-31 1968-01-02 Merck & Co Inc Aerosol unit dispensing uniform amounts of a medically active ingredient
GB1219090A (en) 1967-05-22 1971-01-13 Moore Medicinal Products Ltd Pressurised aerosol dispensers for medicaments
EP0132352A2 (en) 1983-07-15 1985-01-30 Glaxo Group Limited Aerosol applicator device
US5682875A (en) * 1988-10-22 1997-11-04 Fisons Plc Aerosol device having a spout to prevent spray head blockage
US5069204A (en) 1989-08-23 1991-12-03 Riker Laboratories, Inc. Inhaler
US5435297A (en) 1991-08-29 1995-07-25 Christoph Klein Medical device for inhaling metered aerosols
WO1994027663A1 (en) 1993-05-26 1994-12-08 Minnesota Mining And Manufacturing Company Aerosol actuator
GB2312379A (en) 1996-04-25 1997-10-29 Bespak Plc Metered dose inhaler
US20030015191A1 (en) 2001-04-26 2003-01-23 New England Pharmaceuticals, Inc. Metered dose delivery device for liquid and powder agents
EP1321159A1 (en) 2001-12-21 2003-06-25 CHIESI FARMACEUTICI S.p.A. Pressurized metered dose inhaler (pMDI) actuators with laser drilled orifices
US20050274378A1 (en) * 2002-07-25 2005-12-15 Bonney Stanley G Medicament dispenser
US20060118107A1 (en) 2002-10-30 2006-06-08 King Michael L Tubular nozzles for use in systems for delivering medicaments
WO2004091704A1 (en) 2003-04-16 2004-10-28 Trudell Medical International Antistatic medication delivery apparatus
US20070251950A1 (en) * 2003-12-12 2007-11-01 Clinical Designs Limited Dispenser and Counter
GB2415388A (en) * 2004-06-24 2005-12-28 Link Holdings Ltd Medicament dispenser with an insert in the medicament flow path
US20070175469A1 (en) 2005-12-02 2007-08-02 Boehringer Ingelheim International Gmbh, Dispensing device
WO2008017575A1 (en) 2006-08-07 2008-02-14 Bang & Olufsen Medicom A/S An inhaler and a method of dispensing medication to a person
US20100218760A1 (en) 2006-08-22 2010-09-02 Anderson Gregor John Mclennan Actuator for an inhaler
US20110061646A1 (en) 2007-08-21 2011-03-17 Glaxo Group Limited Drug dispenser
US20110155129A1 (en) * 2009-12-23 2011-06-30 Map Pharmaceuticals, Inc. Enhanced eductor design
WO2011095762A1 (en) 2010-02-03 2011-08-11 Bacon Raymond J Dispenser
US20120085345A1 (en) 2010-10-12 2012-04-12 Teva Branded Pharmaceutical Products R&D, Inc. Nasal spray device

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023079173A1 (en) 2021-11-08 2023-05-11 Chiesi Farmaceutici S.P.A. Apparatus for administering medicaments and method for managing expiry dates of a medicament dispenser

Also Published As

Publication number Publication date
WO2014033057A1 (en) 2014-03-06
CA2883749A1 (en) 2014-03-06
TW201420140A (zh) 2014-06-01
AR092274A1 (es) 2015-04-08
CL2015000475A1 (es) 2015-07-03
EP2890437A1 (en) 2015-07-08
SG11201501434PA (en) 2015-03-30
MA37871A1 (fr) 2016-09-30
HK1209669A1 (en) 2016-04-08
MX2015002027A (es) 2015-06-05
IN2015DN01597A (ru) 2015-07-03
AU2013307389A1 (en) 2015-03-19
JP2015531247A (ja) 2015-11-02
US20170080168A1 (en) 2017-03-23
PH12015500208A1 (en) 2015-03-16
CN104582771B (zh) 2018-09-04
IL237428A0 (en) 2015-04-30
CN104582771A (zh) 2015-04-29
EA201590286A1 (ru) 2015-08-31
US20140060531A1 (en) 2014-03-06
KR20150048727A (ko) 2015-05-07
PE20150523A1 (es) 2015-05-07
US10737044B2 (en) 2020-08-11
BR112015002757A2 (pt) 2017-07-04
EA033581B1 (ru) 2019-11-06
TN2015000073A1 (en) 2016-06-29

Similar Documents

Publication Publication Date Title
US10737044B2 (en) Aerosol inhalation device
TWI660747B (zh) 溴化吡咯醣及福莫特羅組合之穩定加壓噴霧溶液組成物
AU2008271599B2 (en) Metered dose inhaler actuator
ES2464520T3 (es) Formulación en aerosol para EPOC
UA75770C2 (en) Actuators for pressurized metered dose inhaler, products of medicinal aerosol solution formulation comprising these actuators, method for manufacturing actuators
JP2006511257A (ja) 医薬送達用システムに使用するための管状ノズル
JP2007507270A (ja) 乾燥散剤吸入器
US11426538B2 (en) Aerosol inhalation device
US20210386730A1 (en) Pharmaceutical formulation containing glycopyrrolate and indacaterol maleate
BR112012015335B1 (pt) formulação de aerossol para doença pulmonar obstrutiva crõnica
KR101857834B1 (ko) 계량된-투여량 흡입기 액츄에이터, 계량된-투여량 흡입기
WO2021150489A1 (en) Inhalable formulation of a solution containing glycopyrrolate and olodaterol hydrochloride
CN115209884B (zh) 含有格隆溴铵和盐酸奥达特罗的可吸入制剂
Ehtezazi Recent patents in pressurised metered dose inhalers
JP2023519524A (ja) 少なくとも２つの液体組成物のエアロゾル送達
WO2021178232A1 (en) Inhalable formulation of a solution containing glycopyrronium bromide
TW201946693A (zh) 微結構噴嘴
BR112012015336B1 (pt) Formulação de aerossol de brometo de glicopirrônio estabilizada com ácido clorídrico para o tratamento de doença pulmonar obstrutiva crônica, uso da mesma e método para carregar um cartucho de aerossol

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150326

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20170720

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20190605

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BRAMBILLA, GAETANO

Inventor name: JOHNSON, ROBERT

Inventor name: LEWIS, DAVID ANDREW

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAR Information related to intention to grant a patent recorded

Free format text: ORIGINAL CODE: EPIDOSNIGR71

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTC Intention to grant announced (deleted)
GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

INTG Intention to grant announced

Effective date: 20191106

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602013064122

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1213893

Country of ref document: AT

Kind code of ref document: T

Effective date: 20200115

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20191218

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200319

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: CHIESI FARMACEUTICI S.P.A.

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200513

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200418

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

REG Reference to a national code

Ref country code: DE

Ref legal event code: R026

Ref document number: 602013064122

Country of ref document: DE

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

PLAX Notice of opposition and request to file observation + time limit sent

Free format text: ORIGINAL CODE: EPIDOSNOBS2

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1213893

Country of ref document: AT

Kind code of ref document: T

Effective date: 20191218

26 Opposition filed

Opponent name: BECK GREENER LLP

Effective date: 20200918

Opponent name: WERRTA GMBH DUESEN- UND ZERSTAEUBUNGSTECHNIK

Effective date: 20200918

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

PLBB Reply of patent proprietor to notice(s) of opposition received

Free format text: ORIGINAL CODE: EPIDOSNOBS3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

RAP4 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: CHIESI FARMACEUTICI S.P.A.

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200823

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200831

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200831

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20200831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200823

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200831

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20210825

Year of fee payment: 9

Ref country code: IT

Payment date: 20210820

Year of fee payment: 9

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20210827

Year of fee payment: 9

Ref country code: GB

Payment date: 20210827

Year of fee payment: 9

REG Reference to a national code

Ref country code: DE

Ref legal event code: R103

Ref document number: 602013064122

Country of ref document: DE

Ref country code: DE

Ref legal event code: R064

Ref document number: 602013064122

Country of ref document: DE

R26 Opposition filed (corrected)

Opponent name: BECK GREENER LLP

Effective date: 20200918

RDAF Communication despatched that patent is revoked

Free format text: ORIGINAL CODE: EPIDOSNREV1

RDAG Patent revoked

Free format text: ORIGINAL CODE: 0009271

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: PATENT REVOKED

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: FI

Ref legal event code: MGE

27W Patent revoked

Effective date: 20211203

GBPR Gb: patent revoked under art. 102 of the ep convention designating the uk as contracting state

Effective date: 20211203

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200418

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20220816

Year of fee payment: 10